Patient Advocacy in Support of Alzheimers Disease Therapeutic - PowerPoint PPT Presentation

Patient Advocacy in Support of Alzheimer’s Disease Therapeutic Research and Development Cynthia A. Bens Vice President, Public Policy February 3, 2014

Increases in Life Expectancy 100 Neanderthal 20 40 60 80 0 20 Classical Rome 28 Medieval England 33 U.S. (1900) 47.3 Current U.S. 77.9

PROJECTED INCREASE IN YOUNG CHILDREN AND OLDER PEOPLE AS A PERCENTAGE OF GLOBAL POPULATION GLOBAL POPULATION BETWEEN 2005 and 2030, BY AGE

Age and Risk of Chronic Disease

Challenges: Alzheimer’s Disease • Last drug successfully approved for treatment 2003 • No treatment to modify the disease course • To date trials have been long and expensive • High risk/no reward proposition for industry (1 success for every 34 failures) • Limited (but growing!) federal research investment

Results of Recent AD Treatment Trials Treatment Result Bapineuzmab Negative Dimebon Negative IVIg (Gammagard) Negative Rosiglitazone Negative Semagacestat Negative Semagacestat Negative Tarenflurbil Negative Tramiprosate Negative Xaliprodan Negative

www.agingresearch.org www.act-ad.org cbens@agingresearch.org